ADD ANI AS A TRUSTED SOURCE
googleads
Menu
Asia

Korea: Genexine, PHI Biomed, and POSTECH to develop COVID-19 mRNA vaccine

Seoul [South Korea] July 13 (ANI/Global Economic): Genexine announced on the 12th that it has signed a joint research agreement with PHI Biomed and POSTECH (Pohang University of Science and Technology) to develop a next-generation COVID-19 mRNA vaccine.

ANI Jul 13, 2021 11:58 IST googleads

Genexine, PHI Biomed, and POSTECH to develop COVID-19 mRNA vaccine (Photo Credits: Genexine)

Seoul [South Korea] July 13 (ANI/Global Economic): Genexine announced on the 12th that it has signed a joint research agreement with PHI Biomed and POSTECH (Pohang University of Science and Technology) to develop a next-generation COVID-19 mRNA vaccine.
According to Genexine, this agreement aims to develop a COVID-19 mRNA vaccine which is safe for the body and has a next-generation delivery system to solve safety issues. The results of the joint research, including technology and intellectual property rights, will be jointly owned by three organizations.
The research team led by Professor Seung Soo Oh of Pohang University of Science and Technology (POSTECH) will conduct research to maximize the preventive effectiveness of vaccines through the design and detailed engineering of mRNAs which is used for COVID-19 vaccines.
PHI Biomed will develop LNP platform technology for delivering new mRNA vaccine. Genexine will lead the cooperation between two organizations based on its experience in developing the COVID-19 DNA vaccine.
The company is expecting that the next-generation mRNA vaccine to be developed will be delivered effectively to the body using hyaluronic acid lipid messengers.(ANI/Global Economic)

Get the App

What to Read Next

Asia

Policy delays leave Pakistan short of critical medicines

Policy delays leave Pakistan short of critical medicines

Pakistan faces a severe shortage of life-saving medicines, including cancer drugs and vaccines, due to government delays in notifying official prices. While global supply remains stable, regulatory hurdles have stalled legal imports, raising concerns over patient survival and the potential rise of unregulated, counterfeit medicines.

Read More
Asia

North Korea accelerates preparations for parliamentary elections

North Korea accelerates preparations for parliamentary elections

North Korea is intensifying preparations for its upcoming parliamentary elections scheduled for next week, including forming election committees and reviewing candidates for the Supreme People's Assembly, according to a report by Yonhap News Agency citing North Korean state media on Wednesday.

Read More
Asia

S Korea says deterrence against North Korea unaffected

S Korea says deterrence against North Korea unaffected

South Korea on Wednesday said its deterrence posture against North Korea would remain unaffected even if some military assets of the United States Forces Korea (USFK) are relocated from the Korean Peninsula amid the conflict in West Asia, Yonhap News Agency reported.

Read More
Asia

"Global South emanates from shared history": EAM Jaishankar

EAM S Jaishankar stated that the era of "big deals" between dominant powers is over, as multipolarity is now an irreversible reality. He argued that the Global South is defined by shared historical experiences, while noting a growing "differentiation" within the previously unified Global West.

Read More
Asia

N Korea ruler oversees cruise missile tests from new destroyer

N Korea ruler oversees cruise missile tests from new destroyer

Kim oversaw the launch of sea-to-surface strategic cruise missiles from the destroyer on Wednesday and assessed the test as a "core" element of the new warship's capabilities, which he described as a "new symbol of sea defence" for his country. "All these successes constitute a radical change in defending our maritime sovereignty, something that we have not achieved for half a century," he said.

Read More
Home About Us Our Products Advertise Contact Us Terms & Condition Privacy Policy

Copyright © aninews.in | All Rights Reserved.